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Cost-effectiveness analysis has been increasingly used in the
field of cardiovascular disease, ever since its first application to
medicine some 20 years ago (1). This technique provides a
method to identify and weigh the benefits of an intervention
against its costs. As discussed in recent overviews of cost-
effectiveness (2–5), the effectiveness of an intervention is
measured in health terms, typically as years of life saved (or as
quality-adjusted life-years, to provide appropriate credit to
interventions that relieve symptoms and improve quality of
life). The costs of the intervention are measured in monetary
terms. The health outcomes and costs of an intervention must
be compared with an alternative, and the incremental cost-
effectiveness ratio is then calculated as follows:
C2 2 C1
LY2 2 LY1
,
where C1 and C2 are the costs of the two alternatives, and LY1
and LY2 are the health outcomes of the two alternatives.
Cost-effectiveness ratios of $50,000/life-year or less are gener-
ally considered worthwhile in the United States because they
compare favorably with the benchmarks provided by the
cost-effectiveness ratios for accepted interventions, such as
renal dialysis, which costs roughly $30,000/year (6).
Cost-effectiveness analysis has been applied most often to
therapeutic interventions, such as thrombolysis for acute myo-
cardial infarction (7), the treatment of elevated cholesterol
levels (8) or the use of the implantable cardioverter-
defibrillator for patients with a previous cardiac arrest (9). The
framework of cost-effectiveness analysis can readily be ex-
tended to diagnostic or prognostic tests, but cost-effectiveness
analyses of such tests pose conceptual and practical challenges.
The result of a test is information about the patient’s diagnosis
or prognosis. Although this information may provide some
direct health benefits through reassurance of the patient (e.g.,
a normal coronary angiogram may reduce worry in a patient
with chest pain), the major value of the test result is in allowing
the physician to choose the therapy best suited for the patient.
In turn, the chosen therapy can then provide specific health
benefits to the patient. Thus, the health benefits of diagnostic
or prognostic testing are largely indirect and are highly depen-
dent on the efficacy of subsequent therapy.
The indirect effect of diagnostic or prognostic tests on
health outcomes implies that the cost-effectiveness of these
tests can be no better than the cost-effectiveness of the
therapies prescribed based on their results. Imagine for a
moment the perfect diagnostic test—100% sensitive, 100%
specific, with no adverse effects and free of cost. If a positive
result on this perfect test identifies a disease for which there is
no effective therapy, then the test will have very little value. If
the therapy provides only a slight benefit at great expense—say,
$10 million dollars/year of life saved—the cost-effectiveness of
even a perfect diagnostic test will be equally unattractive. In
contrast, if therapy is highly cost-effective, then use of a perfect
diagnostic test to look for patients with that disease will also be
highly cost-effective. However, real-world diagnostic tests are
imperfect, with ,100% sensitivity and specificity, nontrivial
monetary costs and, in many cases, some physical risk as well.
False positive test results will lead to more tests or to unnec-
essary treatment, whereas false negative test results may
provide inappropriate reassurance and a potential reduction in
survival. The cost-effectiveness of diagnostic test strategies will
therefore generally be less favorable than the cost-effectiveness
of the associated therapy.
Testing after acute myocardial infarction. Patients with an
acute myocardial infarction have an increased risk of cardiac
death for the 6 to 12 months after hospital discharge (10).
Many of the postinfarction deaths are sudden and unexpected,
presumably due to cardiac arrhythmias. In principle, sudden
deaths might be prevented by appropriate antiarrhythmic
therapy, either drugs or devices such as the implantable
cardioverter-defibrillator. With other therapies of proven ben-
efit in the postinfarction patient (11)—including beta-blockers
(12), aspirin (13), cholesterol-lowering drugs (14,15) and
angiotensin-converting enzyme inhibitors (16)—the risk of
death in the postinfarction year has been reduced considerably.
In this setting, it is not clear that routine antiarrhythmic
therapy can improve health outcomes further. It is logical to
hypothesize that diagnostic testing might be able to identify a
subgroup of patients in whom the risk of sudden death is
sufficiently higher than average that intervention would be
warranted and cost-effective.
The effectiveness of antiarrhythmic drugs in postinfarction
patients has been controversial. Early studies of risk stratifica-
tion after acute myocardial infarction identified reduced left
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ventricular function and ventricular ectopic beats as indepen-
dent adverse prognostic factors (10). The association of ven-
tricular ectopic beats with subsequent sudden death provided a
strong rationale for use of specific antiarrhythmic therapy to
reduce ectopic beats and the risk of cardiac death. The Cardiac
Arrhythmia Suppression Trial (17) tested the postinfarction
use of class I antiarrhythmic drugs and, surprisingly, docu-
mented a significant increase in cardiac death. Quantitative
overviews have also suggested that class I antiarrhythmic
agents actually increase postinfarction mortality (18). In con-
trast, early small randomized trials suggested that amiodarone
might reduce the risk of death in postinfarction patients
(19,20). The recently reported Canadian Amiodarone Myocar-
dial Infarction Arrhythmia Trial (CAMIAT) (21) and Euro-
pean Myocardial Infarction Amiodarone Trial (EMIAT) (22)
confirmed that amiodarone reduced sudden death, but they
did not document a significant reduction in total mortality.
These results have been interpreted as showing that amioda-
rone is ineffective after myocardial infarction (23), but neither
CAMIAT (21) nor EMIAT (22) enrolled enough patients to
exclude a clinically important effect of amiodarone in reducing
total mortality. Recent meta-analyses (24,25) examined all
available randomized trials and suggest that amiodarone does
indeed reduce total mortality significantly by 10% to 20%. If
one accepts that amiodarone is effective in reducing total
mortality after myocardial infarction, the question becomes
which patients, if any, benefit sufficiently from amiodarone to
justify its risk and expense.
The study by Pedretti et al. (26) examined several strategies
to select patients for postinfarction amiodarone treatment.
They examined a noninvasive strategy and a two-step approach
that combines a noninvasive test with the use of an electro-
physiologic study in patients with a positive noninvasive result.
The authors focused on heart rate variability as the prototype
for a noninvasive test, based on encouraging early results in
postinfarction patients (27). However, the specific noninvasive
test chosen was not crucial to the analysis because Pedretti et
al. show that other noninvasive tests might be used with
cost-effectiveness similar to that of heart rate variability (26).
The model used by Pedretti et al. did not consider use of
amiodarone for all postinfarction patients. The authors’ im-
plicit assumption was that routine use of amiodarone would
not be realistic because the risk of sudden death in an
unselected cohort of postinfarction patients is probably too low
to justify use of amiodarone. Although the authors’ assumption
is likely to be correct, it would have nevertheless been helpful
to have included both the “treat all patients” and the “treat no
one” strategies in any cost-effectiveness analysis of the use of
diagnostic testing to select patients for treatment (28). It is only
by comparing these two alternatives against the effect of testing
followed by selective treatment that the effect of diagnostic
testing can be identified separately from the overall effect of
treatment in unselected patients.
The most important result of the report by Pedretti et al.
was that the two-tier strategy of noninvasive/selective invasive
testing was not cost-effective compared with the noninvasive
strategy alone. This conclusion held regardless of whether the
noninvasive test used was heart rate variability or alternative
noninvasive tests alone or in combination. The invasive strat-
egy would be economically attractive only if it had a substan-
tially lower cost or if the sensitivity of invasive testing in the
prediction of sudden death were twice as high as indicated in
studies to date.
A second conclusion of the authors was that noninvasive
testing may be a cost-effective method for identifying and
treating patients at risk for sudden death after myocardial
infarction. This conclusion is suggestive but must be consid-
ered tentative in light of the current uncertainty surrounding
the optimal approach to postinfarction testing. Although Pe-
dretti et al. have attempted to analyze the best available
information on postinfarction test performance, their analysis
can be no stronger than the data on which it rests. Most of the
measures of test performance in the model were based on the
data from a single study of 575 patients drawn from one
hospital (27). We need more information on the performance
of tests such as heart rate variability in larger, relatively
unselected populations to be confident in the test’s ability to
measure risk accurately. In particular, we need to identify tests
or test sequences that identify patients at high risk of sudden
death, yet low risk of nonsudden death. It is in these patients
that the antiarrhythmic therapy has the greatest potential to
improve outcome. Because the cost-effectiveness of diagnostic
tests is closely tied to the efficacy and cost-effectiveness of
therapy selected on the basis of test results, the goal of testing
is to find postinfarction patients for whom antiarrhythmic
therapy provides a clear health benefit at an acceptable cost.
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